Pay in 4 interest-free payments of $5.45 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
The success of brands such as Wegovy and Zepbound has spurred demand beyond diabetic populations, positioning GLP-1 therapies as central to chronic weight management protocols
Eli Lilly published the results of its ATTAIN-1b trial for obesity in September 2025 7 , which compared orforglipron to placebo in more than 3,100 adults without diabetes, with a BMI of 30+ or 27-30 with an obesity-related complication including hypertension, dyslipidaemia, cardiovascular disease or obstructive sleep apnoea and a history of at least one patient-reported unsuccessful dietary effort to lose body weight, who have tried unsuccessfully to lose weight with diet alone
Tell us what you would like to change
:max_bytes(150000):strip_icc()/health-GettyImages-2025836701-ce3f5ccf0f98428e9d14abaeb07ba307.jpg)
doi:10.1128/MCB.24.24.10529-10541.2004
We can, because 94.6% of members never need to use it
US$ 20.24
US$ 29.44
US$ 21.72
US$ 23.28
US$ 29.84
US$ 22.72
